Skip to content

Inventories at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$14.58B+15.2%
Glaukos logo
GlaukosGKOS
$62.38M+4.9%
AbbVie logo
AbbVieABBV
$5.05B+11.6%
Bausch + Lomb logo
Bausch + LombBLCO
$977M-5.2%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$2.53M-0.2%
Boston Scientific logo
Boston ScientificBSX
$3.12B+8.7%

Other financials

Income statement

See full
Revenue$19.7M+12.5%
Gross profit$17.0M+12.5%
Operating income-$12.4M+10.4%
Net income-$13.0M+8.3%
EPS (diluted)-$0.24+14.3%

Balance sheet

See full
Cash & equivalents$85.0M-21.9%
Total debt$40.9M+1.1%
Total equity$53.9M-30.6%
Total assets$109.7M-15.4%

Cash flow

See full
Operating cash flow-$7.0M+39.4%
CapEx$60.0K
Free cash flow-$7.1M+38.9%

Valuation

See full
Market cap$294.9M+35.0%
Enterprise value$250.83M+59.0%
P/S3.7×+0.8×

Profitability

See full
Gross margin86.2%+0.5pp
Operating margin-44.8%-10.2pp
Net margin-46.8%-9.6pp
FCF margin-31.9%+0.2pp

Returns & leverage

See full
Return on equity-56.6%+4.3pp
Debt / equity0.8×+0.2×
Current ratio5.9×-4.6×

Where this comes from

Reported directly by Sight Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sight Sciences, Inc.'s inventories?
Sight Sciences, Inc. (SGHT) reported inventories of $7.01M in Q1 2026.
How has Sight Sciences, Inc.'s inventories changed year-over-year?
Sight Sciences, Inc.'s inventories increased by 20.7% year-over-year, from $5.81M to $7.01M.
What is the long-term trend for Sight Sciences, Inc.'s inventories?
Over 5 years (2020 to 2025), Sight Sciences, Inc.'s inventories has grown at a 24.5% compound annual growth rate (CAGR), from $2.6M to $7.77M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.